References
- American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Attention-Deficit/ Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000;105:1158–70
- Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attentiondeficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997;36:85S–121
- Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005;35:245–56
- Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642–57
- Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237–48
- Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:77–97
- Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909–18
- Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387–95
- Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr 2005;10:6–15
- Boyle L, Moncrief S, Krishnan S. Pharmacokinetics of NRP 104 (lisdexamfetamine dimesylate) following administration of a single intranasal, intravenous, or oral dose in rats. Abstract presented at the 46th Annual Meeting of the New Clinical Drug Evaluation Unit; June 12–15, 2006; Boca Raton, FL, USA
- Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2007;29:450–63
- Findling RL, Childress AC, Krishnan S, et al. Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/hyperactivity disorder. Poster presented at the 160th Annual Meeting of the American Psychological Association; May 19–24, 2007; San Diego, CA, USA
- Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970–6
- Krishnan S, Ermer JC, Kehner G. Effect of food on lisdexamfetamine dimesylate (LDX; NRP104) pharmacokinetics. Abstract presented at the US Psychiatric and Mental Health 19th Annual Congress; November 15–19, 2006; New Orleans, LA, USA
- Auiler JF, Liu K, Lynch JM, et al. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr Med Res Opin 2002;18:311–6
- Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11:625–39